Calcipotriol safety considerations in pediatric psoriasis include which statement?

Calcipotriol safety considerations in pediatric psoriasis include which statement?

• A. It should be used liberally on the entire body
• B. It can cause hypercalcemia when applied over large areas
• C. It is always safe to use with no restrictions
• D. It must be used only in combination with phototherapy

Answer: (B)

Topical calcipotriol can be absorbed through the skin, and in children this systemic absorption is a key safety consideration. The younger the patient and the more skin that’s treated, the greater the potential amount of the drug that enters the circulation. When calcipotriol is absorbed systemically, it acts like a vitamin D analog and increases calcium absorption from the gut and calcium reabsorption by the kidneys, which can lead to hypercalcemia. In pediatric patients, hypercalcemia risk rises when the medication is applied over large areas or used for extended periods. That’s why careful use is recommended—limit application to appropriate, smaller areas, monitor for symptoms (like nausea, vomiting, irritability, polyuria, dehydration), and check calcium levels if large-area or long-term use is necessary. If hypercalcemia occurs, discontinue calcipotriol and manage as needed. Other statements are not correct because treating the entire body liberally is unsafe due to absorption risk, assuming it’s always safe ignores the potential for systemic effects, and requiring phototherapy every time isn’t a necessity for safety or efficacy.

Topical calcipotriol can be absorbed through the skin, and in children this systemic absorption is a key safety consideration. The younger the patient and the more skin that’s treated, the greater the potential amount of the drug that enters the circulation. When calcipotriol is absorbed systemically, it acts like a vitamin D analog and increases calcium absorption from the gut and calcium reabsorption by the kidneys, which can lead to hypercalcemia.

In pediatric patients, hypercalcemia risk rises when the medication is applied over large areas or used for extended periods. That’s why careful use is recommended—limit application to appropriate, smaller areas, monitor for symptoms (like nausea, vomiting, irritability, polyuria, dehydration), and check calcium levels if large-area or long-term use is necessary. If hypercalcemia occurs, discontinue calcipotriol and manage as needed.

Other statements are not correct because treating the entire body liberally is unsafe due to absorption risk, assuming it’s always safe ignores the potential for systemic effects, and requiring phototherapy every time isn’t a necessity for safety or efficacy.